Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
CNS Pharmaceuticals, Inc. (CNSP) had Return on Tangible Equity of -350.48% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-15.85M |
|
-- |
|
-- |
|
$15.99M |
|
$-15.99M |
|
$0.14M |
|
$-15.85M |
|
$-15.85M |
|
$-15.85M |
|
$-15.85M |
|
$-15.85M |
|
$-15.85M |
|
$-15.99M |
|
$-15.98M |
|
0.44M |
|
0.44M |
|
$-35.75 |
|
$-35.75 |
|
| Balance Sheet Financials | |
$8.10M |
|
$0.02M |
|
$0.52M |
|
$8.62M |
|
$4.10M |
|
-- |
|
-- |
|
$4.10M |
|
$4.52M |
|
$4.52M |
|
$4.52M |
|
0.63M |
|
| Cash Flow Statement Financials | |
$-13.81M |
|
$-0.02M |
|
$14.57M |
|
$6.46M |
|
$7.20M |
|
$0.74M |
|
$0.19M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.98 |
|
-- |
|
-- |
|
-- |
|
0.07 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-13.83M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-350.48% |
|
|
Return on Tangible Equity |
-350.48% |
-183.81% |
|
-350.48% |
|
$7.14 |
|
$-31.22 |
|
$-31.18 |
|